Related Experiment Video

Updated: Apr 14, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K

Influence of diabetes on cardiac resynchronization therapy in heart failure patients: a meta-analysis

Hui Sun1, Yuqing Guan2, Lei Wang3

  • 1Department of Cardiology, Jinan Central Hospital, Affiliated with Shandong University, Jinan, Shandong Province, 250013, China. Sunhuisasa303@sohu.com.

BMC Cardiovascular Disorders
|April 17, 2015
PubMed

Insights

Cardiac resynchronization therapy (CRT) reduces mortality in heart failure patients, including those with diabetes. However, diabetic patients still experience higher mortality rates post-CRT compared to non-diabetic individuals.

Area of Science:

  • Cardiology
  • Diabetology
  • Medical Technology

Background:

  • Diabetes mellitus is a significant risk factor for increased morbidity and mortality in heart failure patients.
  • Cardiac resynchronization therapy (CRT) improves cardiac performance and quality of life in heart failure but its impact on mortality in diabetic patients remains unclear.

Purpose of the Study:

  • To evaluate the long-term effects of CRT on mortality in heart failure patients with and without diabetes mellitus.
  • To compare the effectiveness of CRT in reducing mortality between diabetic and non-diabetic heart failure populations.

Main Methods:

  • A meta-analysis was conducted on randomized controlled trials (RCTs) published between 1994 and 2011.
  • Data from 5 RCTs involving 2,923 patients with chronic symptomatic left-ventricular dysfunction were analyzed using a random-effects model.
  • The primary outcome assessed was all-cause mortality.

Main Results:

  • Cardiac resynchronization therapy significantly reduced mortality in both diabetic and non-diabetic heart failure patients.
  • Mortality rates were 24.3% for diabetic patients and 20.4% for non-diabetic patients post-CRT.
  • The odds ratio for mortality in diabetic versus non-diabetic patients was 1.28 (95% CI 1.06-1.55, P=0.010).

Conclusions:

  • CRT may decrease mortality in progressive heart failure patients, irrespective of diabetes status.
  • Despite CRT's benefits, diabetic patients with heart failure may have a higher mortality risk compared to their non-diabetic counterparts.
Abstract

More Related Videos

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

2.3K
Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes11:00

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes

Published on: September 18, 2017

10.7K

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
602
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
803
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
571
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.2K